海普瑞(002399.SZ):參股子公司OncoQuest擬交易資產並實現資產境外上市
格隆匯4月21日丨海普瑞(002399.SZ)公佈,公司通過全資子公司美國海普瑞持有的境外參股子公司OncoQuest 擬向一家韓國上市公司Dual出售其擁有的與免疫治療在研藥品相關的全部權益,包括但不限於藥品的專利權、臨牀試驗申辦者權益及重大合同等。
此次擬出售資產不包括OncoQuest持有的深圳昂瑞股權,同時OncoQuest已授予深圳昂瑞的大中華區域獨家產品開發及商業化權益不受影響,OncoQuest保留參與與該項授權相關活動的權利。
交易完成後,OncoQuest以普通股和可轉債形式持有的Dual股份數約為1.12億股,根據截至2019年4月20日Dual已發行及已承諾發行的普通股和可轉債計算,佔其全面攤薄後總股本的50.7%,為其第一大股東。
OncoQuest擬將持有Dual的普通股及可轉債按照持股比例分配給股東,美國海普瑞預計將直接持有Dual全面攤薄後總股本的17.84%(未實施回售權時)。同時,美國海普瑞將繼續持有OncoQuest全面攤薄後35.18%股權。
Dual通過向OncoQuest發行普通股及可轉債作為購買資產對價,同時Dual擬使用自有資金6500萬美元現金用於支持Oregovomab III期臨牀試驗費用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.